In-Vivo Protein Reagent RNA 
Drug Discovery World
NOVEMBER 30, 2023
This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK. GSK has developed high-throughput mammalian and E.
Drug Discovery World
JULY 18, 2023
Current research is focused on designing CRISPR-enhanced CAR T cells that are resistant to immunosuppressive cytokines such as transforming growth factor-β (TGF-β) 2 , programmed cell death protein (PD-1) 3 , or other negative T cell regulators 4 (CTLA-4, LAG-3, and TIM-3), thus improving anti-tumour functions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
DECEMBER 15, 2022
Potential solutions: For CRISPR systems, the likelihood of off-target editing has been shown to be influenced by a variety of factors, ranging from the design of the gRNA 1 and Cas9 protein 2 , to the targeted cell type 3 , to name a few examples. In vivo approaches involve delivering the gene editing components directly into the patient.
XTalks
APRIL 22, 2022
Flow cytometry is an analytical technique that is used to detect the presence of cell surface markers as well as intracellular proteins using antibodies in individual cells suspended in a buffer solution, which pass through a laser beam one at a time ( Figure 1 ). What is Flow Cytometry?
Drug Discovery World
OCTOBER 20, 2022
used conventional flow cytometry analysis and FACS (fluorescence-activated cell sorting) to validate a pan-CAF marker along with CAF subpopulation-specific markers identified using single-cell RNA sequencing 3. Fibroblasts in the tumour microenvironment. This is of particular importance in dense tissues like breast and pancreas. Elyada et al.
Expert insights. Personalized for you.
59 
Let's personalize your content